Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Clinical trial NCT04933539 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04933539
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-31
- Primary completion
- 2026-08-31
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.